PRODUCT NAME

BALVERSATM (erdafitinib) film-coated tablets.

DOSAGE FORMS AND STRENGTHS

BALVERSATM is formulated as 3 mg, 4 mg, and 5 mg tablets for oral use.

- 3 mg: Yellow, round biconvex shaped, film coated, debossed with "3" on one side; and "EF" on the other side.
- 4 mg: Orange, round biconvex shaped, film coated, debossed with "4" on one side; and "EF" on the other side.
- 5 mg: Brown, round biconvex shaped, film coated, debossed with "5" on one side; and "EF" on the other side.

For excipients, see List of Excipients.

CLINICAL INFORMATION

Indications

BALVERSATM is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC), whose tumors have susceptible fibroblast growth factor receptor (FGFR) 3 genetic alterations, who have disease progression during or following at least one line of prior chemotherapy including within 12 months of neoadjuvant or adjuvant chemotherapy (see *Pharmacodynamic Effects - Clinical Studies*).

Dosage and Administration

Dosage – Adults (≥18 years)

Recommended dose

The recommended starting dose of BALVERSATM is 8 mg orally once daily; with pharmacodynamically guided up-titration, based on serum phosphate concentrations and tolerability at 14 to 21 days, to 9 mg daily if criteria are met (see *Dosage and Administration - Dose Modifications*).

Administration

Before taking BALVERSATM, patients must have confirmation of susceptible FGFR3 gene alterations as confirmed by a validated test (see *Pharmacodynamic Effects - Clinical studies*).

The tablets should be swallowed whole with or without food. If vomiting occurs any time after taking BALVERSATM, the next dose should be taken the next day.

Treatment should continue until disease progression or unacceptable toxicity occurs.

Missed dose

If a dose of BALVERSATM is missed, it can be taken as soon as possible. Resume the regular daily dose schedule for BALVERSATM the next day. Extra tablets should not be taken to make up for the missed dose.

Dose modifications

Pharmacodynamically-guided up-titration based on serum phosphate concentrations

Serum phosphate (PO4) concentrations should be assessed between 14 and 21 days after initiating treatment. Up-titrate the dose to 9 mg daily as soon as possible if that serum phosphate (PO4) concentration is <5.5 mg/dL, and there is no drug-related toxicity.

Dose reduction

For possible dose reductions and management of adverse reactions see Tables 1 to 4.

Dose	1 st dose reduction	2 nd dose reduction	3 rd dose reduction	4 th dose reduction	5 th dose reduction
9 mg →	8 mg	6 mg	5 mg	4 mg	Stop
8 mg 🔶	6 mg	5 mg	4 mg	Stop	

 Table 1:
 BALVERSATM dose reduction schedule

Hyperphosphatemia is an expected, transient laboratory abnormality of FGFR inhibitors (see *Pharmacodynamics Effects*). Phosphate concentrations should be monitored monthly. For elevated phosphate concentrations in patients treated with BALVERSATM follow dose modification guidelines in Table 2. For all patients, phosphate intake should be restricted to 600-800 mg daily. For elevated phosphate concentrations (\geq 7.0 mg/dL) in patients treated with BALVERSATM, follow the dose modification guidelines in Table 2, and addition of a non-calcium containing phosphate binder (e.g., sevelamer carbonate) should be considered.

Table 2:Recommended dose modifications based on serum phosphate concentrations with use of
BALVERSATM after up-titration

Serum phosphate concentration	BALVERSA TM Dose Management ^a
<6.9 mg/dL	Continue BALVERSA TM at current dose.
(<2.2 mmol/L)	
7.0-9.0 mg/dL	Withhold BALVERSA TM for a week, reassess phosphate concentrations
(2.3-2.9 mmol/L)	weekly until concentration returns to <5.5 mg/dL and then re-start
	BALVERSA TM at the same dose level.
	A dose reduction may be implemented for persistent ^b hyperphosphatemia
>9.0 mg/dL	Hold BALVERSA [™] for up to 28 days, with weekly reassessments until
(>2.9 mmol/L)	concentration returns to < 5.5 mg/dL (or baseline). Then restart
	BALVERSA TM at 1 dose level below.
> 10.0 mg/dL (> 3.2 mmol/L) or	Withhold BALVERSA TM with weekly reassessments until level returns to
significant alteration in baseline	< 5.5 mg/dL (or baseline). Then may restart BALVERSA TM at 2 dose
renal function or Grade 3	levels lower.
hypercalcemia	

For all patients, restrict phosphate intake to 600-800 mg/day.

^b Persistent hyperphosphatemia is considered to be more than 1 sequential (at least 1 week apart) phosphate value of >7 mg/dL

Eye disorder management

Prior to initiating BALVERSATM, perform a baseline ophthalmological exam including an Amsler grid test, fundoscopy, visual acuity and, if available, an optical coherence tomography (OCT).

To prevent and treat dry eyes, use artificial tear substitutes, hydrating or lubricating eye gels or ointments frequently, at least every 2 hours during waking hours. Severe treatment-related dry eye should be evaluated by an ophthalmologist.

Subsequently examine patients monthly, including an Amsler grid test, and if any abnormality is observed, follow the management guidelines in Table 3.

Severity Grading	BALVERSA TM Dose Management
Grade 1:	Refer for an ophthalmologic examination (OE). If an OE cannot be performed within
Asymptomatic or mild	7 days, withhold BALVERSA [™] until an OE can be performed.
symptoms; clinical or	If no evidence of drug-related corneal or retinal pathology on OE, continue
diagnostic observations	BALVERSA [™] at same dose level.
only, or abnormal Amsler	If diagnosis from OE is keratitis or retinal abnormality (i.e., CSR ^a /RPED ^b), withhold
grid test.	BALVERSA [™] until resolution. If reversible in 4 weeks on OE, resume at next lower
	dose.
	Monitor for recurrence for a month. Consider re-escalation if no recurrence.
Grade 2:	Immediately withhold BALVERSA [™] and refer for an OE.
Moderate; limiting age	If no drug-related corneal or retinal pathology on OE, withhold BALVERSA [™] until
appropriate instrumental	resolution.
activities of daily living	Resume BALVERSA [™] at the next lower dose level.
(ADL).	If diagnosis from OE is keratitis or retinal abnormality (i.e. CSR/RPED), withhold
	BALVERSA [™] until resolution.
	If resolved (complete resolution and asymptomatic) within 4 weeks on OE, resume
	BALVERSA TM at the next lower dose level. Monitor for recurrence every 1 to 2
	weeks for a month.
Grade 3:	Immediately withhold BALVERSA [™] and refer for an OE.
Severe or medically	If resolved (complete resolution and asymptomatic) within 4 weeks, then
significant but not	BALVERSA TM may be resumed at 2 dose levels lower. Monitor for recurrence every
immediate sight-	1 to 2 weeks for a month.
threatening; limiting self-	Consider permanent discontinuation of BALVERSA TM for recurrence.
care ADL.	
Grade 4:	Permanently discontinue BALVERSA TM .
Sight-threatening	Monitor until complete resolution or stabilization.
consequences; blindness	
(20/200 or worse).	

 Table 3:
 Guideline for management of eye disorders with use of BALVERSATM

^a CSR-central serous retinopathy

^b RPED-retinal pigment epithelium detachment

Dose modification for other adverse reactions

Skin, mucosal, and nail changes have been observed with BALVERSATM. Follow dose modification guidelines in Table 4.

Severity of Adverse Reaction ^a	BALVERSATM	
Nail Disorder	BALVERSA TM Dose Management	
Grade 1	Continue at current dose.	
Grade 2	Continue at current dose.	
Grade 3	Withhold BALVERSA TM until resolves to Grade 1 or baseline, then may resume at 1 dose level lower.	
Grade 4	Permanently discontinue.	
Skin Disorder		
Grade 1	Continue at current dose.	
Grade 2	Continue at current dose. Consider withholding if no improvement in 1 week. When resolves to \leq Grade 1 or baseline, restart at same or 1 dose level below.	
Grade 3	Withhold BALVERSA TM until resolves to Grade 1 or baseline, then may resume at 1 dose level lower.	
Grade 4	Permanently discontinue.	
Mucositis		
Grade 1	Continue at current dose.	
Grade 2	Continue at current dose. Consider withholding if no improvement in 1 week. When resolves to \leq Grade 1 or baseline, restart at same or 1 dose level below.	
Grade 3	Withhold BALVERSA TM until resolves to Grade 1 or baseline, then may resume at 1 dose level lower.	
Grade 4	Permanently discontinue.	

Table 4: Recommended dose modifications for adverse reactions with use of BALVERSATM

^a Dose adjustment graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

Special populations

Pediatrics (17 years of age and younger)

The safety and efficacy of erdafitinib in children have not been established. No data are available.

Elderly (65 years of age and older)

Of the 416 patients treated with BALVERSA[™] in clinical studies, 45% were 65 years of age or older, and 12% were 75 years of age or older. No overall differences in safety and effectiveness were observed between elderly and younger patients. No specific dose adjustments are considered necessary for elderly patients (see *Pharmacokinetic Properties*).

Renal impairment

Based on population pharmacokinetic (PK) analyses, no dose adjustment is required for patients with mild or moderate renal impairment (see *Pharmacokinetic Properties*). No data are available in patients with severe renal impairment.

Hepatic impairment

Based on PK analyses, no dose adjustment is required for patients with mild or moderate hepatic impairment (see *Pharmacokinetic Properties*). Limited data are available in patients with severe hepatic impairment.

Contraindications

None.

Warnings and Precautions

Ocular disorders

As with other tyrosine kinase inhibitors, ocular disorders may occur with the administration of BALVERSATM. The most commonly reported CSR events were chorioretinopathy (8%), retinal detachment (5%), and detachment of retinal pigment epithelium (RPED, 5%). CSR was observed in 23 patients (23%) treated with BALVERSATM in study BLC2001 at the 8 mg daily dose, with a median time to first onset of 50 days. An abnormal Amsler grid test result was identified in the majority (70%) of patients who developed CSR, mostly Grade 1 and 2. In study BLC2001, CSR resolved in 12 patients and 11 patients had ongoing events of which many had improved in severity and the majority were Grade 1. Grade 3 CSR/RPED, involving central field of vision, was reported in 3% of patients. CSR/RPED resolved in 13% of patients and was ongoing in 13% of patients, respectively and three patients (3%) discontinued BALVERSATM. Ocular disorders other than CSR occurred in 55% of patients, including dry eye (19%) and vision blurred (17%). Dry eye symptoms occurred in 28% of patients during treatment with BALVERSATM and were Grade 3 in 6% of patients. All patients should receive dry eye prophylaxis with ocular demulcents as needed.

Screen patients for eye disorders prior to initiating treatment with BALVERSATM using an Amsler grid test, fundoscopy, visual acuity and if available an OCT. To prevent and treat dry eyes, use artificial tear substitutes, hydrating or lubricating eye gels or ointments frequently, at least every 2 hours during waking hours. Refer severe treatment-related dry eye to an ophthalmologist for evaluation. Examine patients monthly thereafter and if any abnormality is observed, or at any time a patient reports eye-related events or visual disturbance, follow the management guidelines in Table 3 (see *Dosage and Administration*).

Embryo-fetal toxicity

Based on findings in animal reproduction studies, erdafitinib can cause fetal harm when administered to a pregnant woman. In a rat embryo-fetal toxicity study, erdafitinib was embryotoxic and teratogenic and oral administration of erdafitinib to pregnant rats during the period of organogenesis caused malformations and embryo-fetal death at exposures less than the human exposures at all doses studied (see *Dosage and Administration*). Advise pregnant women of the potential risk to the fetus. Advise female patients of reproductive potential to use highly effective contraception prior to and during treatment, and for 3 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with BALVERSATM and for 3 months after the last dose (see *Pregnancy, Breast-feeding, Contraception, and Fertility*).

Hyperphosphatemia

Increases in phosphate levels are a pharmacodynamic effect of BALVERSATM (see *Pharmacodynamic Properties*). Hyperphosphatemia was reported as adverse reaction in 76% of patients treated with BALVERSATM. The median onset time for any grade event of hyperphosphatemia was 20 days (range: 8 –116) after initiating BALVERSATM. Thirty-two percent of patients received phosphate binders during treatment with BALVERSATM.

Monitor for hyperphosphatemia and follow the dose modification guidelines when required (see *Dosage and Administration*).

Interactions

Effect of other drugs on BALVERSA™

Moderate CYP2C9 or strong CYP3A4 inhibitors

Co-administration with a moderate CYP2C9 or strong CYP3A4 inhibitor increased erdafitinib exposure and may lead to increased drug-related toxicity (see *Pharmacokinetic Properties – Drug interactions*). Consider alternative agents with no or minimal enzyme inhibition potential. If BALVERSATM is co-administered with a moderate CYP2C9 or strong CYP3A4 inhibitor, reduce the BALVERSATM dose based on tolerability (see *Dosage and Administration*). If the moderate CYP2C9 or strong CYP3A4 inhibitor is discontinued, the BALVERSATM dose may be adjusted as tolerated.

Strong CYP2C9 or CYP3A4 inducers

Co-administration with strong CYP2C9 or CYP3A4 inducers may lead to decreased erdafitinib exposure (see *Pharmacokinetic Properties*). Consider alternative agents with no or minimal enzyme induction potential. If BALVERSATM is co-administered with a CYP2C9 or CYP3A4 inducer, the dose might be cautiously increased by 1 to 2 mg and adjusted gradually every two to three weeks based on clinical monitoring for adverse reactions. If the strong inducer is discontinued, the BALVERSATM dose may be adjusted as tolerated.

Moderate CYP2C9 or CYP3A4 inducers

Co-administration with strong CYP2C9 or CYP3A4 inducers may lead to decreased erdafitinib exposure (see Pharmacokinetics). If a moderate CYP2C9 or CYP3A4 inducer must be co-administered at the start of BALVERSATM treatment, administer BALVERSATM dose as recommended (8 mg once daily with potential to increase to 9 mg once daily based on serum phosphate levels on Days 14 to 21 and tolerability). If a moderate CYP2C9 or CYP3A4 inducer

must be co-administered after the initial dose increase period based on serum phosphate levels and tolerability, increase BALVERSATM dose up to 9 mg. When a moderate inducer of CYP2C9 or CYP3A4 is discontinued, continue BALVERSATM at the same dose, in the absence of drug-related toxicity.

Serum Phosphate Level-Altering Agents

Co-administration of BALVERSATM with other serum phosphate level-altering agents may increase or decrease serum phosphate levels (see *Pharmacodynamic effects*). Changes in serum phosphate levels due to serum phosphate level-altering agents (other than erdafitinib) may interfere with serum phosphate levels needed for the determination of initial dose increased based on serum phosphate levels (see *Dosage and Administration*). Avoid co-administration of serum phosphate level-altering agents with BALVERSATM before initial dose increase period based on serum phosphate levels (Days 14 to 21) (see *Dosage and Administration*).

Effect of BALVERSA™ on other drugs

P-Glycoprotein (P-gp) substrates

Concomitant administration of BALVERSATM with P-gp substrates may increase their systemic exposure if administered concurrently (see *Pharmacokinetic Properties*). Oral narrow therapeutic index P-gp substrates such as digoxin should be taken at least 6 hours before or after erdafitinib to minimize the potential for interactions.

CYP3A4 substrates

Co-administration of BALVERSATM with CYP3A4 substrates may alter the plasma concentrations of CYP3A4 substrates. Avoid co-administration of BALVERSATM with sensitive substrates of CYP3A4 with narrow therapeutic indices.

OCT2 substrates

Co-administration of BALVERSATM with OCT2 substrates may increase the plasma concentrations of OCT2 substrates. Consider alternative therapies that are not OCT2 substrates or consider reducing the dose of OCT2 substrates (e.g., metformin) based on tolerability.

Pregnancy, Breast-feeding, Contraception, and Fertility

Pregnancy

There are no available human data informing the erdafitinib-associated risk. Based on findings in animal reproduction studies, erdafitinib can cause fetal harm when administered to a pregnant woman. In a rat embryo-fetal toxicity study, erdafitinib was embryotoxic and teratogenic at exposures less than the human exposures at all doses studied (see *Dosage and Administration*). Fetal toxicity was characterized by hand/foot defects and malformations of some major blood vessels, such as the aorta.

If BALVERSATM is used during pregnancy, or if the patient becomes pregnant while taking BALVERSATM, advise the patient of the potential hazard to the fetus and counsel the patient about her clinical and therapeutic options. Advise patients to contact their healthcare professional

if they become pregnant or pregnancy is suspected while being treated with BALVERSATM and up to 3 months afterwards.

Breast-feeding

There are no data on the presence of erdafitinib in human milk, or the effects of BALVERSATM on the breast-fed infant, or on milk production. Because of the potential for serious adverse reactions from BALVERSATM in breast-fed infants, advise women not to breast-feed during treatment with BALVERSATM and for 3 months following the last dose of BALVERSATM.

Pregnancy testing

Pregnancy testing with a highly sensitive assay is recommended for females of reproductive potential prior to initiating BALVERSATM.

Contraception

BALVERSATM can cause fetal harm when administered to pregnant women. Advise female patients of reproductive potential to use highly effective contraception prior to and during treatment, and for 3 months after the last dose of BALVERSATM. Male patients must use effective contraception (e.g., condom) and not donate or store semen during treatment and for 3 months after the last dose of BALVERSATM.

Fertility

Based on findings from animal studies, BALVERSATM may impair fertility in females of reproductive potential. No human data are available to determine potential effects of BALVERSATM on fertility in males or females.

Effects on Ability to Drive and Use Machines

No studies to establish the effects of erdafitinib on the ability to drive and use machines have been conducted. However, eye disorders such as central serous retinopathy or keratitis have been noted with FGFR inhibitors and with BALVERSATM treatment. If patients experience treatment-related symptoms affecting their vision, it is recommended that they do not drive or use machines until the effect subsides (see *Warnings and Precautions*).

Adverse Reactions

Throughout this section, adverse reactions (ARs) are presented. Adverse reactions are adverse events (AEs) that were considered to be reasonably associated with the use of erdafitinib based on the comprehensive assessment of the available adverse event information. A causal relationship with erdafitinib cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety data described below reflect exposure to BALVERSATM in study BLC2001 a Phase 2 study including 99 patients with locally advanced or metastatic urothelial carcinoma and whose

tumors had certain FGFR genetic alterations as detected by a clinical trial assay in a central laboratory, and who have disease progression during or following at least one line of prior chemotherapy including within 12 months of neoadjuvant or adjuvant chemotherapy. Patients were treated with BALVERSATM at 8 mg orally once daily; with pharmacodynamically guided up-titration to 9 mg in patients with phosphate concentrations <5.5 mg/dL. Median duration of treatment was 5.3 months (range: 0 to 17 months).

The most common ARs $\geq 15\%$ were hyperphosphatemia (77%), stomatitis (58%), dry mouth (45%), decreased appetite (38%) dry skin (32%), alopecia (29%), palmar-plantar erythrodysesthesia syndrome (23%), dry eye (19%), onycholysis (18%), paronychia (17%) and nail dystrophy (16%). The most common G3 ARs >1% were stomatitis (10%), nail dystrophy (6%), palmar-plantar erythrodysesthesia syndrome (5%), paronychia (3%), nail disorder (3%), keratitis (3%), onycholysis (2%) and hyperphosphatemia (2%). Adverse reactions leading to dose reduction occurred in 52% of patients, including twenty (20%) for eye disorders. Only nine patients (9%) experienced ARs leading to treatment discontinuation, including three (3%) for eye disorders.

Table 5 presents ARs reported in $\geq 1\%$ of patients treated with BALVERSATM at 8 mg once daily in study BLC2001.

			8 mg daily (N=99)	
MedDRA system organ class		All grades	Grade 3	Grade 4
(SOC)	Adverse reaction	(%)	(%)	(%)
Metabolism and nutrition disorders	Hyperphosphatemia	77	2	0
	Decreased appetite	38	0	0
Gastrointestinal disorders	Stomatitis	58	10	0
	Dry mouth	45	0	0
	Diarrhoea	51	4	0
	Constipation	28	1	0
	Nausea	20	1	0
	Vomiting	13	2	0
Skin and subcutaneous tissue disorders	Dry skin	32	0	0
	Alopecia	29	0	0
	Palmar-plantar erythrodysesthesia syndrome	23	5	0
	Onycholysis	18	2	0
	Paronychia	17	3	0
	Nail dystrophy	16	6	0
	Nail discoloration	11	0	0
	Nail disorder	8	3	0
	Onychalgia	5	0	0
	Pruritus	5	0	0
	Skin fissures	4	0	0
	Nail ridging	3	0	0
	Onychoclasis	3	1	0
	Eczema	1	0	0
	Hyperkeratosis	1	0	0
	Skin exfoliation	1	0	0

Table 5:Adverse reactions reported in $\geq 1\%$ of patients treated with BALVERSATM

	Skin lesion	1	0	0
Eye disorders	Dry eye	19	1	0
	Conjunctivitis	13	0	0
	Chorioretinopathy	8	0	0
	Detachment of retinal pigment epithelium	5	1	0
	Keratitis	5	3	0
	Retinal detachment	5	0	0
	Retinal edema	3	1	0
	Xerophthalmia	3	0	0
	Retinopathy	2	1	0
	Ulcerative keratitis	2	0	0
	Vitreous detachment	2	0	0
Respiratory, thoracic and mediastinal disorders	Nasal dryness	9	0	0
	Oropharyngeal pain	10	1	0
General disorders and administration site conditions	Mucosal dryness	2	0	0
	Fatigue*	51	9	0
	Pyrexia	13	0	0
Nervous system disorders	Dysgeusia	37	1	0
Infections and infestations	Paronychia	17	3	0
	Urinary tract infection	16	5	0
	Conjunctivitis	13	0	0
Renal and urinary tract disorders	Hematuria	10	2	0
Musculoskeletal and connective tissue disorders.	Musculoskeletal pain**	18	0	0
	Arthralgia	8	0	0

* Includes asthenia, fatigue, lethargy, and malaise ** Includes back pain, musculoskeletal discomfort, musculoskeletal pain, musculoskeletal chest pain, neck pain, pain in extremity

Laboratory Abnormalities Reported in >= 10% (All Grade) or >= 5% (Grade 3-4); Treated Table 6: patients (Study 42756493-BLC2001)

patients (Study +2750+75-DEC2001)			
_	BALVERSA [™] 8 mg daily (N=98 ^a)		
_	All Grades (%)	Grade 3-4 (%)	
Laboratory Abnormality			
Hematology			
Anemia	35	3	
Leukopenia	17	0	
Thrombocytopenia	16	1	
Neutropenia	11	2	
Chemistry			
Hyperphosphatemia	77	2	
Creatinine increased	52	4	
Alanine aminotransferase increased	42	2	
Hyponatremia	41	16	
Alkaline phosphatase increased	39	1	
Hypoalbuminemia	34	0	
Aspartate aminotransferase increased	32	0	
Hypomagnesemia	29	1	
Hypophosphatemia	26	8	
Hypercalcemia	20	3	
Hyperkalemia	14	0	

Table 6:Laboratory Abnormalities Reported in >= 10% (All Grade) or >= 5% (Grade 3-4); Treated
patients (Study 42756493-BLC2001)

BALVERSA TM 8 mg daily (N=98 ^a)		
All Grades (%)	Grade 3-4 (%)	

^a One of the 99 patients had no laboratory tests.

The following ARs were reported with the administration of BALVERSATM in BLC2001 and other studies:

Central serous retinopathy (CSR)

CSR has been reported with the use of BALVERSATM as well as with other FGFR inhibitors. Adverse reactions of CSR were reported in 23% of patients; CSR included chorioretinopathy, retinal detachment, detachment of macular retinal pigment epithelium, detachment of retinal pigment epithelium, retinal edema, retinopathy and vitreous detachment (see *Warnings and Precautions*).

Nail disorders

Nail disorders were reported in 57% of patients and included onycholysis, paronychia, nail dystrophy, nail discoloration, onychalgia, nail ridging, onychoclasis, nail bed bleeding and nail discomfort. The incidence of nail disorders increased with increased exposure. The median time to onset for any grade nail disorder was 68 days.

Skin disorders

Skin disorders were reported in 51% of patients and included dry skin and palmar-plantar erythrodysesthesia syndrome, pruritus, skin fissures, eczema, hyperkeratosis, skin exfoliation, skin lesion, xeroderma, skin atrophy, eczema nummular and skin toxicity. The median time to onset for any grade skin disorder was 40 days.

Hyperphosphatemia

Increases in phosphate concentrations are an expected and transient laboratory abnormality (see *Pharmacodynamic Effects*). Hyperphosphatemia was reported as an adverse event in 77% of patients treated with BALVERSATM. No event of hyperphosphatemia was reported as serious. The median onset time for any grade event of hyperphosphatemia was 20 days. Mean phosphate elevations peaked approximately 6 weeks after the start of BALVERSATM and subsequently decreased to below 4.5 mg/dL by approximately month 5.

Overdose

Symptoms and signs

There is no information on overdosage with BALVERSATM.

Treatment

There is no known specific antidote for BALVERSATM overdose. In the event of an overdose, stop BALVERSATM, undertake general supportive measures until clinical toxicity has diminished or resolved.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic Properties

Pharmacotherapeutic group: Tyrosine kinase inhibitor, ATC code: L01EX16.

Mechanism of action

Erdafitinib is a highly selective and potent oral pan-FGFR tyrosine kinase inhibitor with high affinity and inhibitory activity at low nanomolar levels for all FGFR family members, FGFR 1, 2, 3 and 4. In FGFR pathway activated cancer cell lines, the concentration required for 50% tumor growth inhibition (IC₅₀) is in the low nanomolar range 0.1 to 129.2 nM.

Erdafitinib demonstrated antitumor activity in FGFR-driven cell lines and xenograft models derived from multiple tumor types, including bladder cancer.

Pharmacodynamic Effects

Cardiac electrophysiology

Erdafitinib had no large effects (i.e.,>20 ms) on cardiac repolarization or other electrocardiographic parameters in humans. Exposure-QT analyses were conducted over a dose range from 0.5 to 12 mg from 187 subjects with cancer in a Phase 1, open label, dose escalation study.

Serum phosphate

Erdafitinib increased serum phosphate concentration, a pharmacodynamic biomarker of FGFR inhibition. BALVERSATM should be increased to the maximum recommended dose to achieve target serum phosphate levels of 5.5–7.0 mg/dL in early cycles with continuous daily dosing.

In erdafitinib clinical trials, the use of drugs which can increase serum phosphate levels, such as potassium phosphate supplements, vitamin D supplements, antacids, phosphate-containing enemas or laxatives, and medications known to have phosphate as an excipient were prohibited unless no alternatives exist. To manage phosphate elevation, phosphate binders were permitted. Avoid concomitant use with agents that can alter serum phosphate levels before the initial dose increase period based on serum phosphate levels (see *Dosage and Administration*).

Clinical studies

Urothelial carcinoma tumors with select FGFR genetic alterations

Study BLC2001 was a multicenter, open-label, single arm Phase 2 study to evaluate the efficacy and safety of BALVERSATM in 99 patients with locally advanced or metastatic urothelial

carcinoma, including 12 patients who were chemo-naïve based on ineligibility for cisplatin. All patients were enrolled based on investigator assessment of measurable disease and were required to have tumor tissues with at least 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C or 1 of the following FGFR gene fusions: FGFR3-TACC3, FGFR3-BAIAP2L1, FGFR2-BICC1, FGFR2-CASP7, as determined by a clinical trial assay performed at a central laboratory. The efficacy analysis was based on 87 patients whose disease progressed on or after at least one prior chemotherapy. Patients received a starting dose of BALVERSATM at 8 mg once daily with a pharmacodynamically guided up-titration to 9 mg once daily in patients whose serum phosphate levels between days 14 and 17 were below the target of 5.5 mg/dL; up-titration occurred in 41% of patients. BALVERSATM was administered until disease progression or unacceptable toxicity.

The median age was 67 years (range: 36 to 87 years), 79% were male, and 74% were Caucasian. Most patients (92%) had a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Half of the patients (51%) received one prior line of therapy, 49% received two or more and 79% had visceral metastases. Efficacy results were based on objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (see Table 7).

	IRRC ^a assessment	Investigator assessment	
Endpoint	N=87	N=87	
Objective response rate (ORR) (%)	32.2	40.2	
95% CI (%)	(22.4, 42.0)	(29.9, 50.5)	
Complete response (CR) (%)	2.3	3.4	
Partial response (PR) (%)	29.9	36.8	
Stable disease (SD) (%)	46.0	39.1	
Progressive disease (PD) (%)	18.4	18.4	
Disease control rate (CR+PR+SD) (%)	78	79.3	
95% CI (%)	(69.5, 86.8)	(70.8, 87.8)	
Median Duration of Response (months)	5.4	5.6	
95% CI (%) (months)	(4.2, 6.9)	(4.2, 7.0)	
Time to response (months)	1.4	1.4	
range (months)	(1.2, 4.0)	(1.3, 5.5)	
Median Progression Free Survival (months)	5.5	5.5	
95% CI (%) (months)	(4.0, 5.6)	(4.0, 5.7)	
Median Overall Survival (months)	12.0		
95% CI (%) (months)	(8.6, NE)		

 Table 7:
 Efficacy results for study BLC2001

^a IRRC: Independent Radiologic Review Committee

ORR = CR + PR

CI = Confidence Interval

Investigator assessment demonstrated ORRs for patients receiving BALVERSATM were consistent regardless of the number of lines of prior systemic therapy and ranged from 36% to 60% and Disease Control Rates (DCRs) ranged from 75% to 90%.

ORR by investigator was higher in patients with serum phosphate $\geq 5.5 \text{ mg/dL}$ (43.5% with serum phosphate $\geq 5.5 \text{ mg/dL}$ versus 33.3% with serum phosphate < 5.5 mg/dL as obtained within the first 3 months of treatment). Overall survival was longer in patients with serum phosphate $\geq 5.5 \text{ mg/dL}$ (median overall survival 13.8 months with serum phosphate $\geq 5.5 \text{ mg/dL}$ versus 7.23 months with serum phosphate < 5.5 mg/dL versus 7.23

 Table 8:
 Efficacy Results by FGFR Genetic Alteration

	BIRC ^a assessment
FGFR3 Point Mutation	N=64
ORR (95% CI)	40.6% (28.6, 52.7)
FGFR3 Fusion ^{b, c}	N=18
ORR (95% CI)	11.1% (0, 25.6)

^a BIRC: Blinded Independent Review Committee

^b Both responders had FGFR3-TACC3_V1 fusion

^e One patient with a FGFR2-CASP7/FGFR3-TACC3_V3 fusion is reported in both FGFR2 fusion and FGFR3 fusion above

ORR = CR + PR

CI = Confidence Interval

Pharmacokinetic Properties

Following single and repeat once daily dosing, erdafitinib exposure (maximum observed plasma concentration [C_{max}] and area under the plasma concentration time curve [AUC]) increased in a dose-proportional manner across the dose range of 0.5 to 12 mg. Steady state was achieved after 2 weeks with once daily dosing and the mean accumulation ratio was 4-fold. Following administration of 8 mg once daily, the proposed starting dose, mean (coefficient of variation [CV%]) erdafitinib steady-state C_{max} , AUC_t, and minimum observed plasma concentration (C_{min}) were 1399 ng/mL (50.8%), 29268 ng.h/mL (59.9%), and 936 ng/mL (64.9%). Daily fluctuations in erdafitinib plasma concentrations were low, with a mean (CV%) peak-to-trough ratio of 1.47 (23%) at steady state upon daily dosing.

Absorption

After single dose oral administration, median time to achieve peak plasma concentration (t_{max}) was 2.5 hours (range: 2 to 6 hours) and oral absorption is near complete.

Effect of food

Administration of erdafitinib to healthy subjects under fasting conditions and with a high-fat meal did not result in clinically relevant changes in C_{max} and AUC. Median time to reach t_{max} was delayed about 1.5 hours with food (see *Dosage and Administration*).

Distribution

The mean apparent volume of distribution of erdafitinib in subjects with cancer was 28.8 L.

In patients with cancer, erdafitinib was 99.76% bound to human plasma proteins, preferentially to α 1- acid glycoprotein AGP.

Elimination

Mean total apparent clearance (CL/F) of erdafitinib was 0.362 L/h in patients.

The mean effective half-life of erdafitinib in patients was 58.9 hours.

Metabolism

Metabolism is the main route of elimination for erdafitinib. Erdafitinib is primarily metabolized in human by CYP2C9 and CYP3A4 to form the O-demethylated major metabolite. The contribution of CYP2C9 and CYP3A4 in the total clearance of erdafitinib is estimated to be 39% and 20% respectively. Unchanged erdafitinib was the major drug-related moiety in plasma, there were no circulating metabolites.

Excretion

Up to 16 days following a single oral administration of radiolabeled $[^{14}C]$ -erdafitinib, 69% of the dose was recovered in feces (14-21% as unchanged erdafitinib) and 19% in urine (13% as unchanged erdafitinib).

Special populations

No clinically meaningful differences in the pharmacokinetics of erdafitinib were observed based on age (21-88 years), sex, race (Hispanic or Asian), body weight (36-132 kg), mild or moderate renal impairment and mild or moderate hepatic impairment.

Pediatrics

Pharmacokinetics of erdafitinib has not been studied in pediatric patients.

Renal impairment

No clinically meaningful differences in the pharmacokinetics of erdafitinib were observed between subjects with normal renal function (eGFR-MDRD [estimated glomerular filtration rate-modification of diet in renal disease] $\geq 90 \text{ mL/min/1.73 m}^2$), and subjects with mild (eGFR-MDRD 60 to 89 mL/min/1.73 m²) and moderate renal impairment (eGFR-MDRD 30-59 mL/min/1.73 m²). No data are available in patients with severe renal impairment; therefore BALVERSATM should be administered with caution in these patients. Monitor closely for adverse reactions, and reduce the BALVERSATM dose (see *Dose modifications*).

Hepatic impairment

No clinically meaningful differences in the pharmacokinetics of erdafitinib were observed in subjects with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment and subjects with normal hepatic function based on PK analysis. Limited data are available in patients with severe hepatic impairment; therefore, BALVERSATM should be administered with caution in these patients. Monitor closely for adverse reactions and reduce the BALVERSATM dose (see *Dose modifications*).

CYP2C9 poor metabolizer

Erdafitnib exposure was comparable in subjects with CYP2C9 *1/*2 and *1/*3 genotypes relative to subjects with wild type and similar results were obtained in simulations. No data are available in subjects characterized by other genotypes (e.g., *2/*2, *2/*3, and *3/*3). Simulation suggested no clinically meaningful changes of erdafitinib exposure in CYP2C9 *2/*2 and *2/*3 subjects. The exposure of erdafitinib is predicted to increase by 50% in subjects of CYP2C9

*3/*3 genotype, estimated to be 0.4% to 3% of the population among various ethnic groups and representing the worst-case scenario among the various heterogenous 2C9 poor metabolizer populations.

Drug interactions

Effect of other drugs on erdafitinib

Moderate CYP2C9 inhibitor

Erdafitinib mean ratios (90% CI) for C_{max} and AUC_{∞} were 121% (99.9, 147) and 148% (120, 182), respectively, when co-administered with fluconazole, a moderate CYP2C9 and CYP3A4 inhibitor, relative to erdafitinib alone.

Strong CYP3A4 inhibitor

 C_{max} of erdafitinib was 105% (90% CI: 86.7, 127) and AUC_{∞} was 134% (90% CI: 109, 164) when co-administered with itraconazole, a strong CYP3A4 inhibitor and P-gp inhibitor, relative to erdafitinib alone.

Strong CYP3A4/2C9 inducer

The effects of CYP3A4 or CYP2C9 inducers on the PK of erdafitinib have not been evaluated *in vivo*. Simulations suggested that rifampicin (a strong CYP3A4/2C9 inducer) may lead to approximately 60% decrease in erdafitinib exposure (AUC and C_{max}).

Acid lowering agents

Erdafitinib is a BCS Class I compound with adequate solubility across the pH range of 1 to 7.4. Acid lowering agents (e.g., antacids, H₂-antagonists, or proton pump inhibitors) are not expected to affect the bioavailability of erdafitinib.

Drugs affecting transporters

Erdafitinib is a substrate for P-gp but not for BCRP, OATP1B1, and OATP1B3. P-gp inhibitors are not expected to affect the PK of erdafitinib in a clinically relevant manner.

Sevelamer

No clinically meaningful differences in the pharmacokinetics of erdafitinib were observed in patients taking sevelamer.

Effect of erdafitinib on other drugs

Major CYP isoform substrates

Erdafitinib is not an inhibitor of major CYP isozymes at clinically relevant concentrations; however, it was shown to be a weak time dependent inhibitor towards CYP3A4 activity as well as a weak inducer of CYP3A4. Simulation supported that drug interactions with CYP3A4 substrates are not expected to be clinically relevant.

P-gp transporter

Erdafitinib is a P-gp inhibitor *in vitro* and may be a clinical inhibitor of gut P-gp. Simulation predicted a C_{max} -ratio of 1.45 and an AUC-ratio of 1.18 for digoxin when erdafitinib was co-administered with digoxin at the same time with a C_{max} -ratio of 1.45 and an AUC-ratio of 1.18, whereas dose staggering by 6 hours could avoid this interaction.

Other transporters

Erdafitinib is not an *in vitro* inhibitor of OATP1B3, OAT1, and OAT3. At clinically relevant concentrations, erdafitinib is not considered to be an inhibitor of BCRP, OATP1B, OCT1, MATE-1, and MATE-2K transporters. Erdafitinib is an OCT2 inhibitor *in vitro*. Simulations with metformin, a OCT2 substrate, predicted a lack of clinically relevant interaction with erdafitinib.

NON-CLINICAL INFORMATION

In repeated dose toxicity studies in rats and dogs, disturbance of phosphate homeostasis, characterized by elevated serum concentrations of mainly phosphate, FGF-23 and 1,25 dihydroxyvitamin D₃ were observed at exposures less than the human exposures at all doses studied (see *Dosage and Administration*). Cartilage dysplasia and soft tissue mineralization, associated with hyperphosphatemia, were observed as primary drug-related toxicities in animals. When rats were given a diet supplemented with the phosphate scavenger sevelamer, the soft tissue mineralizations were reduced. Atrophy of gland and epithelial structures (dental changes, thinning of the corneal epithelium lacrimal gland atrophy changes to haircoat and nails) were seen.

Soft tissue mineralizations (except for the aorta mineralization in dogs) and chondroid dysplasia in rats and dogs and mammary gland atrophy in rats were partially to fully recovered at the end of a 4-week drug-free recovery period.

Carcinogenicity, Mutagenicity, and Fertility

Long-term animal studies have not been conducted to evaluate the carcinogenic potential of erdafitinib. Erdafitinib did not induce mutations in the bacterial reverse mutation (Ames) assay and was not genotoxic in either *in vitro* micronucleus or the *in vivo* rat bone marrow micronucleus assay. Dedicated animal fertility studies have not been conducted with erdafitinib. However, in the 3-month general toxicity study, erdafitinib showed effects on female reproductive organs (necrosis of the corpora lutea) in rats at an exposure approximating the AUC in patients at maximum recommended dose of 9 mg, QD.


Reproductive Toxicology

Erdafitinib was teratogenic and embryotoxic in rats at $\geq 4 \text{ mg/kg/day}$ and exposures less than the human exposures at all doses studied (see *Dosage and Administration*). Fetal malformations and variations included limb/paw defects (ectrodactyly, absent or misshapen long bones), malformed thoracic and lumbar vertebrae, great blood vessel abnormalities (high arched/retroesophageal aorta, retroesophageal subclavian artery), and retarded ossifications.

PHARMACEUTICAL INFORMATION

Erdafitinib, the active ingredient in BALVERSATM, is a kinase inhibitor. The chemical name is N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine. Erdafitinib is a yellow powder. It is practically insoluble, or insoluble to freely soluble in organic solvents, and slightly soluble to practically insoluble, or insoluble in aqueous media over a wide range of pH values. The molecular formula is $C_{25}H_{30}N_6O_2$ and molecular weight is 446.56.

Chemical structure of erdafitinib is as follows:



List of Excipients

Tablet Core: Croscarmellose sodium, Magnesium stearate (from vegetable source), Mannitol, Meglumine, and Microcrystalline cellulose.

Film coating (Opadry amb II): Glycerol monocaprylocaprate Type I, Polyvinyl alcohol-partially hydrolyzed, Sodium lauryl sulfate, Talc, Titanium dioxide, Iron oxide yellow, Iron oxide red (for the orange and brown tablets only), Ferrosoferric oxide/iron oxide black (for the brown tablets only).

Shelf Life

See expiry on the outside of the packaging.

Storage Conditions

Store at or below 30°C. Keep out of the sight and reach of children.

Nature and Contents of Container

Tablets are supplied in child resistant blister packs and bottles.

BALVERSA[™] is available in PVC PCTFE foil blisters with an aluminum push through foil sealed inside a wallet pack.

3mg tablets foil blisters come in pack sizes of 56 tablets and 84 tablets. 4mg tablets foil blisters come in pack sizes of 14 tablets (starter pack), 28 tablets, and 56 tablets 5mg tablets foil blisters come in pack sizes of 28 tablets. Not all pack sizes may be marketed. BALVERSA[™] is available in a white 40 cc HDPE bottle with a child-resistant PP closure and an induction seal liner.

Not all presentations may be available locally.

Instructions for Use and Handling [and Disposal]

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

BATCH RELEASER

Janssen Cilag SpA Via C. Janssen, Borgo San Michele, Latina 04100, Italy

PRODUCT REGISTRANT

Under licence from Astex Therapeutics Limited.

Johnson & Johnson Pte Ltd 2 Science Park Drive #07-13, Ascent Singapore Science Park 1 Singapore 118222

DATE OF REVISION OF TEXT

20 January 2022 (CCDS 29 October 2021)